Although attempts are continually being made to find a relevant drug, there are no registered effective drugs targeting mutant KRAS, besides recently registered sotorasib for locally advanced or metastatic NSCLC patients with KRAS G12C mutation, who have received at least one prior systemic therapy, based on the CodeBreaK 100 study (Table 1) [49]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.